Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

American College of Cardiology Meeting In Brief: Merck's Prinivil

Executive Summary

Merck's Prinivil: Retrospective, subgroup analysis of diabetic patients from the GISSI-3 trial shows that treatment with Prinivil (lisinopril) within 24 hours of a suspected myocardial infarction results in a significant decrease in mortality at six weeks for both non-insulin dependent and insulin dependent diabetics, Giulio Zuanetti, Istituto Mario Negri, Milan, reported March 25 at ACC. NIDD patients (n=1,130) receiving lisinopril show a 22% reduction in mortality at six weeks compared to 1,164 NIDD patients receiving placebo, and IDD patients receiving lisinopril (n=254) show a 44.4% reduction in mortality at six weeks compared to 242 IDD patients receiving placebo. Survival rates for both NIDD and IDD patients receiving lisinopril at six weeks was 91% compared to 80% for NIDD and IDD patients on placebo (p=.0005)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027936

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel